pSivida Receives First R&D Payments from Pfizer
News Feb 21, 2008
pSivida Limited has announced the receipt of US$500k as the first quarterly research and development payment from Pfizer under the terms of the exclusive worldwide Collaborative Research and License Agreement signed in April 2007 for pSivida’s controlled drug delivery technologies in ophthalmic applications.
Over the last 10 months pSivida has received US$12m from Pfizer, including equity investments, under the terms of that agreement and will receive up to an additional US$153.5m in development and sales related milestones. Pfizer is the largest shareholder in Company holding approximately 10% of the outstanding shares.
“We are very pleased that the Pfizer licensing agreement is proceeding as expected,” said pSivida’s Managing Director, Dr Paul Ashton.
Lab Innovations 2018 – Registration Opens and Keynotes AnnouncedNews
Learn and earn CPD points at the UK’s only lab-dedicated showcase and scientific seminar series.READ MORE
BioAscent Secures Investment to Expand its Integrated Drug Discovery ServicesNews
£1.6m investment recognises BioAscent’s unique capabilities.READ MORE
GE Focuses Portfolio for Growth and Shareholder Value CreationNews
Healthcare to become standalone company; GE expects to monetize 20% and distribute remaining 80% of GE Healthcare to shareholders tax-free.READ MORE